| Qiagen N.V. (QGEN) | |||
|---|---|---|---|
| 55.45 7.88 (16.57%) | 01-20 16:00 | ||
| Open: | 46.27 | Pre. Close: | 47.57 |
| High: | 57.815 | Low: | 46.07 |
| Volume: | 15,020,432 | Market Cap: | 11,423(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 67.53 One year: 78.87 |
| Support: | Support1: 49.59 Support2: 44.51 |
| Resistance: | Resistance1: 57.81 Resistance2: 67.53 |
| Pivot: | 47.46 |
| Moving Averages: | MA(5): 49.21 MA(20): 47.00 MA(100): 46.38 MA(250): 45.01 |
| MACD: | MACD(12,26): 1.15 Signal(12,26,9): 0.52 |
| %K %D: | %K(14,3): 77.94 %D(3): 72.88 |
| RSI: | RSI(14): 80.49 |
| 52-Week: | High: 57.82 Low: 37.63 Change(%): 16.7 |
| Average Vol(K): | 3-Month: 1527 10-Days: 2933 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 57.852 - 58.126 | 58.126 - 58.384 |
| Low: | 45.494 - 45.753 | 45.753 - 45.996 |
| Close: | 54.949 - 55.429 | 55.429 - 55.879 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ QGEN ] has closed above the upper band by 32.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 121.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue. |
| Company profile |
|---|
| QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands. |
| Stock chart |
|---|
 |
| Stock News |
|---|
|
Wed, 21 Jan 2026 Qiagen Explores Possible Sale After New Buyer Talks: Report - Benzinga Wed, 21 Jan 2026 Qiagen (QGEN) Soars 16.6%: Is Further Upside Left in the Stock? - Yahoo Finance Wed, 21 Jan 2026 QIAGEN NV : Buy rating from Jefferies - marketscreener.com Wed, 21 Jan 2026 Qiagen (QGEN) hits 4-year high as earnings loom - MSN Tue, 20 Jan 2026 Qiagen (NYSE:QGEN) Sets New 52-Week High - Still a Buy? - MarketBeat Tue, 20 Jan 2026 Qiagen (QGEN) Shares Surge Amid Takeover Speculation - GuruFocus |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Medical - Diagnostics & Research | |
| Shares Out. (M) | 206.00 |
| Shares Float (M) | 203.89 |
| % Held by Insiders | 0.45 |
| % Held by Institutions | 81.43 |
| Shares Short (K) | 6490 |
| Shares Short Prior Month (K) | 5860 |
| Stock Financials | |
|---|---|
| EPS | 1.950 |
| Book Value (p.s.) | 17.720 |
| Profit Margin | 19.58 |
| Operating Margin | 25.78 |
| Return on Assets (ttm) | 8.2 |
| Return on Equity (ttm) | 11.3 |
| Qtrly Rev. Growth | 6.1 |
| Gross Profit (p.s.) | 8.058 |
| Sales Per Share | 10.049 |
| EBITDA (p.s.) | 4.951 |
| Qtrly Earnings Growth | 32.50 |
| Operating Cash Flow (M) | 657.70 |
| Levered Free Cash Flow (M) | 666.94 |
| Stock Valuation | |
|---|---|
| PE Ratio | 28.44 |
| PEG Ratio | |
| Price to Book value | 3.13 |
| Price to Sales | 5.52 |
| Price to Cash Flow | 17.37 |
| Stock Dividends | |
|---|---|
| Dividend | 0.250 |
| Dividend Yield | |
| Dividend Growth | |
